At its spinning factory in Oita, Japan, Asahi Kasei Medical, a pioneer in viral filtration, is increasing manufacturing capacity for hydrophilic PVDF (polyvinylidene fluoride) hollow-fibre membranes for Planova BioEX filters. The COVID-19 pandemic has increased demand for Planova filters, which are required to develop and mass-produce anti-coronavirus drugs
Asahi Kasei Medical will use cutting-edge technologies to increase spinning manufacturing capacity at its factory in Miyazaki, Japan. The capacity expansion is planned to begin in the fourth quarter of 2022. To accommodate the increased demand, all six current units, including the spinning mill, have been working effectively and without interruption.
Asahi Kasei Medical is the global market leader in viral filtering, with their Planova filters having been used in the manufacture of biotherapeutics for over 30 years. The company’s goal is to deliver “Assurance Beyond Expectation” in the form of innovative yet incredibly dependable bioprocess consumables, equipment, scientific assistance, and biosafety testing services. It will continue to invest in manufacturing facilities to strengthen its worldwide supply infrastructure for Planova.
